4/A: Zura Bio Ltd: Officer Michael Howell Corrects Transaction Code in Form 4 Amendment

Michael Howell, an officer of Zura Bio Ltd, files an amendment to a previously submitted Form 4 to correct the transaction code for a purchase of Class A ordinary shares.

Summary

• Michael Howell, an officer of Zura Bio Ltd, filed an amended Form 4 with the SEC.
• The amendment corrects an administrative error in the original filing from April 24, 2024.
• The corrected form reflects the accurate transaction code 'A' (acquisition) instead of the previously reported 'P'.
• The transaction involves the acquisition of 7,987 Class A ordinary shares at a price of $3.13 per share on April 22, 2024.
• These shares are indirectly beneficially owned through Mountaineer Biosciences, Inc., where Howell is a Co-Founder and has voting and disposal power.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting an error, indicating standard corporate governance practices. It doesn't inherently suggest positive or negative sentiment, but accuracy in reporting is viewed favorably.

Management Comments

• The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
• This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for company insiders reporting transactions in their company's securities, ensuring transparency and compliance with SEC regulations.

Related Party Transactions

• The acquisition of shares through a private placement with Mountaineer Biosciences, Inc., where Michael Howell is a Co-Founder, constitutes a related party transaction.

Stakeholder Impact

• The correction of the transaction code ensures accurate information for shareholders and potential investors.

Key Dates